OTR Therapeutics has emerged from stealth and announced the successful completion of a $100m Series A financing.
The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital.
Founded in March 2025, OTR Therapeutics said it is establishing a “novel, scalable, and capital-efficient model that synergizes internal R&D with strategic curation of high-potential external innovation.” This integrated approach enables the company to focus on scientific rigour and operational agility, leveraging its deep regional insights and the development efficiency of the local ecosystem to accelerate innovative therapies to patients worldwide.
The proceeds of the financing will advance OTR’s pipeline of differentiated programmes that target significant treatment gaps in immunology and inflammation, oncology, and other disease areas. The funds will also expand OTR’s R&D hub capability.
In line with its strategy, OTR also announced the acquisition of a preclinical programme with best-in-class potential for neurological diseases with high unmet needs. This acquisition is part of the company’s strategic and ongoing efforts to identify and advance promising early-stage assets into global clinical development, alongside its internal proprietary discovery programs to address a broader range of critical patient needs.
“The rapidly evolving global pharmaceutical R&D landscape demands greater novelty, speed and efficiency,” said Zhui Chen, founder and CEO of OTR Therapeutics.
“At OTR, we aim to build a next-generation biotech model that delivers unprecedented R&D and capital efficiency. It enables us to stay agile while remaining rigorously focused on propelling novel, differentiated drug candidates through global clinical translation in a disciplined and efficient manner. We are grateful for the strong support from our investors and their confidence in our vision and capability to deliver transformative therapies for patients.”
The company was co-founded by Chen, Shannon Chuai, and Yuan Shi.